Alten completes integration of Larix and Cmed into CRO business
Alten Group has expanded Aixial Group – its clinical research organization (CRO) - having completed the integration of recent acquisitions Larix and Cmed.
The CRO – which has a team of more than 1,000 employees– will offer a range of services clinical operations, data management and biostatistical consulting, safety, regulatory affairs, quality assurance and medical writing.
Alten count Larix in 2019, citing its presence in Scandinavia as the major motivation for the deal. It acquired Cmed in 2021 highlighting the UK contractor’s capabilities in oncology, immuno-oncology, cell therapy and rare diseases, and the delivery of data and analytic services as key.
Aixial managing director Luca Ferro cited the acquisitions as key, commenting “after a successful transition, Cmed, and Larix have now seamlessly integrated into the Aixial Group.
”Our reinforced expertise in oncology, cell and gene, and rare disease therapies, combined with our commitment and flexibility, enable us to deliver the most efficient clinical trials possible.”
The firm cited Aixial as a driver during its Q1 results presentation explaining it had seen business grow by 15.7% in the period - +12.2% in France and +17.5% outside France.
It wrote that “Almost all business sectors are growing – more specifically Civil Aeronautics, Automotive, Defense & Security, Life Sciences, Electronics.”
Deputy CEO, Bruno Benoliel, cited Europe as a key growth market explaining “In the Benelux, growth is 18% and also went up, actually sped up this quarter in the Netherlands, where the very strong growth dynamic in the last two years kept going up by over 20% thanks to the semiconductors and electronics.
“Belgium, which had a much lower growth rate, also went up by over 15% of the thanks to the recovery of pharmaceutical accounts.”
He also predicted further expansion of the market, adding “Life sciences are going up by 6%. In equipment as well, there are the pharmaceutical sectors.”
Unsplash/chrisliverani